MX2020005079A - Derivados de aminotiazol utiles como agentes antiviricos. - Google Patents

Derivados de aminotiazol utiles como agentes antiviricos.

Info

Publication number
MX2020005079A
MX2020005079A MX2020005079A MX2020005079A MX2020005079A MX 2020005079 A MX2020005079 A MX 2020005079A MX 2020005079 A MX2020005079 A MX 2020005079A MX 2020005079 A MX2020005079 A MX 2020005079A MX 2020005079 A MX2020005079 A MX 2020005079A
Authority
MX
Mexico
Prior art keywords
antiviral agents
derivatives useful
aminothiazole derivatives
aminothiazole
medicaments
Prior art date
Application number
MX2020005079A
Other languages
English (en)
Inventor
Christian Gege
Gerald Kleymann
Original Assignee
Innovative Molecules Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55701658&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020005079(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innovative Molecules Gmbh filed Critical Innovative Molecules Gmbh
Publication of MX2020005079A publication Critical patent/MX2020005079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

La invención se refiere a nuevos compuestos de la Fórmula (I) (Ver formula), a un proceso para su preparación y a su uso como medicamentos, en particular como medicamentos antivíricos.
MX2020005079A 2016-04-06 2018-10-04 Derivados de aminotiazol utiles como agentes antiviricos. MX2020005079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16000787 2016-04-06

Publications (1)

Publication Number Publication Date
MX2020005079A true MX2020005079A (es) 2020-08-13

Family

ID=55701658

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012116A MX2018012116A (es) 2016-04-06 2017-04-05 Derivados de aminotiazol utiles como agentes antiviricos.
MX2020005079A MX2020005079A (es) 2016-04-06 2018-10-04 Derivados de aminotiazol utiles como agentes antiviricos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018012116A MX2018012116A (es) 2016-04-06 2017-04-05 Derivados de aminotiazol utiles como agentes antiviricos.

Country Status (27)

Country Link
US (2) US10590094B2 (es)
EP (1) EP3440063B1 (es)
JP (1) JP6918823B2 (es)
KR (1) KR102354411B1 (es)
CN (1) CN109071473B (es)
AR (1) AR108175A1 (es)
AU (1) AU2017245679B2 (es)
BR (1) BR112018070448A2 (es)
CA (1) CA3018026A1 (es)
CL (1) CL2018002811A1 (es)
CO (1) CO2018010689A2 (es)
CR (1) CR20180482A (es)
CU (1) CU24519B1 (es)
EA (1) EA035401B1 (es)
EC (1) ECSP18074962A (es)
ES (1) ES2834051T3 (es)
GE (1) GEP20207128B (es)
IL (1) IL261421A (es)
MX (2) MX2018012116A (es)
MY (1) MY198018A (es)
PE (1) PE20181804A1 (es)
PH (1) PH12018501979A1 (es)
SV (1) SV2018005760A (es)
TW (1) TWI706940B (es)
UA (1) UA123734C2 (es)
UY (1) UY37193A (es)
WO (1) WO2017174640A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107118207B (zh) * 2017-05-22 2020-10-02 苏州东南药业股份有限公司 一类cdk抑制剂的制备方法
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN116783171A (zh) 2020-10-29 2023-09-19 创新分子股份有限公司 作为抗病毒化合物的氘化氨基噻唑化合物
TW202337444A (zh) 2022-01-17 2023-10-01 德商創新分子有限責任公司 解旋酶引子酶抑制劑的固體結晶形式及其製備方法
WO2024049760A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Cyclic urea thiazolyl compounds for treatment of hsv
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
NZ331104A (en) 1995-12-29 2000-03-27 Boehringer Ingelheim Ca Ltd Phenyl thiazole derivatives that inhibit herpes replication by inhibiting the herpes helicase primase enzyme complex
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
JP2002506858A (ja) 1998-03-19 2002-03-05 ファルマシア・アンド・アップジョン・カンパニー Ｃｍｖ感染症の治療に有用な１，３，４−チアジアゾール
WO2000053591A1 (de) 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE19959958A1 (de) 1999-12-13 2001-08-30 Bayer Ag Thiazolylharnstoff-Derivate
DE19927415A1 (de) 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
DE10039265A1 (de) 2000-08-11 2002-02-21 Bayer Ag Thiazolylamid-Derivate
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
WO2001096874A1 (en) 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
DE10044353A1 (de) 2000-09-07 2002-04-04 Bayer Ag Unkompetitive Inhibitoren der Helikase-Primase
DE10044328A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonyl-Derivate
DE10044358A1 (de) 2000-09-07 2002-03-21 Bayer Ag Thiazolylcarbonylheterocyclyl-Derivate
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129715A1 (de) 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
DE10210319A1 (de) 2002-03-08 2003-09-18 Bayer Ag Thiazolylcarbonyl-Derivate
DE10235967B4 (de) 2002-08-06 2005-09-08 Bayer Healthcare Ag Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung
DE10300109A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Methode zur Inhibition der Replikation von Herpesviren
AU2005210474B2 (en) * 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
AU2011323682B2 (en) * 2010-11-01 2016-06-23 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Also Published As

Publication number Publication date
CA3018026A1 (en) 2017-10-12
CN109071473B (zh) 2022-12-09
CO2018010689A2 (es) 2018-10-22
TWI706940B (zh) 2020-10-11
ECSP18074962A (es) 2018-11-30
EA035401B1 (ru) 2020-06-08
PE20181804A1 (es) 2018-11-19
CU24519B1 (es) 2021-06-08
KR102354411B1 (ko) 2022-01-21
SV2018005760A (es) 2019-03-08
CR20180482A (es) 2019-04-09
AR108175A1 (es) 2018-07-25
CL2018002811A1 (es) 2019-02-08
EP3440063B1 (en) 2020-08-05
BR112018070448A2 (pt) 2019-02-05
UY37193A (es) 2017-11-30
TW201738217A (zh) 2017-11-01
UA123734C2 (uk) 2021-05-26
MY198018A (en) 2023-07-26
CN109071473A (zh) 2018-12-21
MX2018012116A (es) 2019-05-23
AU2017245679A1 (en) 2018-10-04
JP2019515883A (ja) 2019-06-13
CU20180124A7 (es) 2019-04-04
US20190112285A1 (en) 2019-04-18
EA201892246A1 (ru) 2019-04-30
JP6918823B2 (ja) 2021-08-11
ES2834051T3 (es) 2021-06-16
EP3440063A1 (en) 2019-02-13
KR20180132674A (ko) 2018-12-12
IL261421A (en) 2018-10-31
US10590094B2 (en) 2020-03-17
AU2017245679B2 (en) 2021-07-01
WO2017174640A1 (en) 2017-10-12
GEP20207128B (en) 2020-07-10
PH12018501979A1 (en) 2019-07-01
US20200148652A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
PH12018502516A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502515A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3675B1 (ar) مشتقات هيدروكسي إستر جديدة،عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
PH12017502266B1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017014035A (es) Formas solidas novedosas.
TW201613864A (en) Novel compounds
CR20200154A (es) Enantiómeros de tiazoles sustituidos como compuestos antivirales
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PH12018501709A1 (en) Naphthridinedione derivatives
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
LV14852A (lv) Triazolilpurīna atvasinājumi kā pretvīrusu preparāti
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.